Edition:
United States

Idera Pharmaceuticals Inc (IDRA.OQ)

IDRA.OQ on NASDAQ Stock Exchange Capital Market

8.45USD
21 Sep 2018
Change (% chg)

$0.13 (+1.56%)
Prev Close
$8.32
Open
$8.22
Day's High
$8.47
Day's Low
$8.00
Volume
311,198
Avg. Vol
106,121
52-wk High
$22.92
52-wk Low
$5.22

Chart for

About

Idera Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapeutics for oncology and rare diseases. The Company utilizes two drug discovery technology platforms to design and develop drug candidates, which include Toll-like receptor (TLR) targeting... (more)

Overall

Beta: 2.40
Market Cap(Mil.): $226.09
Shares Outstanding(Mil.): 27.17
Dividend: --
Yield (%): --

Financials

  IDRA.OQ Industry Sector
P/E (TTM): -- 108.45 32.71
EPS (TTM): -2.83 -- --
ROI: -81.24 1.54 12.72
ROE: -82.01 0.30 14.84

BRIEF-Idera Pharmaceuticals Reports Q1 Loss Per Share $0.10

* IDERA PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

May 09 2018

BRIEF-Idera Pharmaceuticals Enters Into A Clinical Development Support Agreement With Pillar Partners Foundation

* IDERA PHARMACEUTICALS ENTERS INTO A CLINICAL DEVELOPMENT SUPPORT AGREEMENT WITH PILLAR PARTNERS FOUNDATION TO EXPAND THE CLINICAL RESEARCH ON IMO-2125 BEYOND PD-1 REFRACTORY MELANOMA

Apr 16 2018

BRIEF-Biocryst Pharmaceuticals And Idera Pharmaceuticals Reschedule Meetings To Vote On Proposed Merger

April 10 Idera Pharmaceuticals Inc - New Clinical Data On Idera's Imo :

Apr 10 2018

BRIEF-Idera Pharma Files Definitive Proxy Statement Over With Pending Merger With Biocryst

* IDERA PHARMACEUTICALS FILES DEFINITIVE PROXY STATEMENT IN CONNECTION WITH PENDING MERGER WITH BIOCRYST PHARMACEUTICALS

Apr 02 2018

BRIEF-RA Capital Management Opposes BioCryst Pharmaceuticals' Proposed Merger With Idera Pharmaceuticals

* RA CAPITAL MANAGEMENT OPPOSES BIOCRYST PHARMACEUTICALS' PROPOSED MERGER WITH IDERA PHARMACEUTICALS

Apr 02 2018

BRIEF-Biocryst Pharmaceuticals Files Definitive Proxy Statement Related To Pending Merger With Idera Pharmaceuticals

* BIOCRYST PHARMACEUTICALS FILES DEFINITIVE PROXY STATEMENT IN CONNECTION WITH PENDING MERGER WITH IDERA PHARMACEUTICALS

Apr 02 2018

Earnings vs. Estimates